Hier finden Sie den Zugang zur Notfallseite, Kontaktinformationen, Barrierefreiheits-Einstellungen, die Sprachwahl und die Suchfunktion.

Navigation öffnen
Eine Mann füllt mit einer Pipette eine rote Flüssigkeit in ein kleines Glas

Aktuelle Publikationen


Sie befinden sich hier:

Aktuelle Publikationen aus Klinik und Forschung (Auswahl)

der Medizinischen Klinik mit Schwerpunkt Hämatologie, Onkologie und Tumorimmunologie (CBF)


Jung P, Schmalbrock L, Wirth M.: CRISPR Activation/Interference Screen to Identify Genetic Networks in HDAC-Inhibitor-Resistant Cells. Methods Mol Biol. 2023

Liebig S, Neumann M, Silva P, Ortiz-Tanchez J, Schulze V, Isaakidis K, Schlee C, (...) Burmeister T, Schwartz S, Gökbuget N, Mochmann LH, Baldus CD.: FAT1 expression in T-cell acute lymphoblastic leukemia (T-ALL) modulates proliferation and WNT signalingSci Rep. 2023

Meesters S, Bazata J, Handtke V, (...) Bausewein C, Schildmann E; SedPall Study Group.: "It's pretty much flying blind in the home care setting": A qualitative study on the influence of home care specific circumstances on sedation in specialist palliative home care. Palliat Med. 2023



Seidel C, Hentrich M, Zschäbitz S, (...), Ochsenreither S, (...) Schwab C, Bokemeyer C, Oing C.: Peritoneal carcinosis in male germ cell tumor patients: a registry study compiled by the German Testicular Cancer Study Group (GTCSG). World J Urol. 2022

Schick M, Zhang L, Maurer S, (...), Isaakaidis K, (...) Rohleder E, (...) Habringer S, (...) Chapuy B, Wirth M, Wolf E, Rad R, Müller S, Keller U.: Genetic alterations of the SUMO isopeptidase SENP6 drive lymphomagenesis and genetic instability in diffuse large B-cell lymphomaNat Commun. 2022

Graessle R, Stromberger C, Heiland M, (...) Klinghammer K, (...) Dommerich S, Piwonski I, Coordes A.: Predictors for Adherence to Treatment Strategies in Elderly HNSCC Patients. Cancers (Basel). 2022

Horak P, Griffith M, Danos AM, (...), Rieke D, (...) Griffith OL, Chakravarty D, Sonkin D.: Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med. 2022 

Wilke AC, Doebele C, Zindel A, (...) Chapuy B, (...) Staudt LM, Zenz T, Oellerich.: SHMT2 inhibition disrupts the TCF3 transcriptional survival program in Burkitt lymphoma. Blood. 2022

Drilon A, Tan DSW, Lassen UN, Leyvraz S, (...) Moreno V, Kummar S, Lin JJ.: Efficacy and Safety of Larotrectinib in Patients With Tropomyosin Receptor Kinase Fusion-Positive Lung Cancers. JCO Precis Oncol. 2022 

Wirth M.: Targeting the translational machinery to overcome apoptosis resistance in pancreatic cancer. Transl Oncol. 2022

Maschmeyer P, Haas S.: ATACing single cells with phages. Mol Cell. 2022

Jacob AS, Kaul H, Fuchs M, (...) Mathas S, (...) Hallek M, Borchmann P, Lehmann C. Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma. Infection. 2022

Lier S, Sellmer A, Orben F, (...) Wirth M, Saur D, Mahboobi S, Schneider G.: A novel Cereblon E3 ligase modulator with antitumor activity in gastrointestinal cancer. Bioorg Chem. 2022

Rieger K, (...) Peuker CA, Pezzutto A, Pinto A, Keller U, Scholz CW.: 90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 years. Ann Hematol. 2022

Klinghammer K, Lorini L, Nevens D, Simon C, Machiels JP, Bossi P.: Treatment Stratification in First-Line Recurrent or Metastatic Head and Neck Cancer, on Behalf of the EORTC Young Investigator Head and Neck Cancer Group. Front Oncol. 2022

Jacob AS, Kaul H, Fuchs M, (...) Mathas S, (...) Hallek M, Borchmann P, Lehmann C.: Impact of the first COVID-19 lockdown in Germany on the rate of acute infections during intensive chemotherapy for Hodgkin lymphoma. Infection. 2022

Doffo J, Bamopoulos SA, Köse H, (...), Zang C, (...) Habringer S, (...) Schick M, (...) Keller U, Schneider G, Wirth M.: NOXA expression drives synthetic lethality to RUNX1 inhibition in pancreatic cancer. Proc Natl Acad Sci USA. 2022

Ng YLD, Ramberger E, (...) Dolnik A, (...) Müller S, (...) Keller U, Bullinger L, Mertins P, Krönke J. Proteomic profiling reveals CDK6 upregulation as a targetable resistance mechanism for lenalidomide in multiple myeloma. Nat Commun. 2022

Schneeweis C, Hassan Z, Ascherl K, Wirth M, (...) Robles MS, Saur D, Schneider G. Indirect targeting of MYC sensitizes pancreatic cancer cells to mechanistic target of rapamycin (mTOR) inhibition. Cancer Commun (Lond). 2022 

Dao T, Mun SS, Molvi Z, (..), Klatt MG, (...) Lorenz IC, O'Reilly RJ, Scheinberg DA. A TCR mimic monoclonal antibody reactive with the "public" phospho-neoantigen pIRS2/HLA-A*02:01 complexJCI Insight. 2022

Wasilewski D, Janz M, Koch A, Rosenwald A, Keller U, (...) Faust K, Anagnostopoulos I, Radke J.: A peculiar case of primary central nervous system T-cell lymphoma with indolent behavior.  Acta Neurol Belg. 2022

Braitsch K, Schwarz A, Koch K, (...) Keller U, (...) Bassermann F, Herhaus P, Verbeek M.: Conditioning with fludarabine and treosulfan compared to FLAMSA-RIC in allogeneic stem cell transplantation for myeloid malignancies: a retrospective single-center analysis. Ann Hematol. 2022

Hess G, Hüttmann A, Witzens-Harig M, (...) Keller U, (...) Rosenwald A, Theobald M, Lenz G.: A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trial. Br J Haematol. 2022 

Izquierdo E, Vorholt D, Blakemore SJ, (...) Chapuy B, (...) Krüger M, Hallek M, Pallasch CP.: Extracellular vesicles and PDL1 suppress macrophages inducing therapy resistance in TP53-deficient B-cell malignancies. Blood. 2022

Trumpp A, Haas S.: Cancer stem cells: The adventurous journey from hematopoietic to leukemic stem cells. Cell. 2022

Fiskin E, Lareau CA, Ludwig LS, (...) Ring AM, Xavier RJ, Regev A.: Single-cell profiling of proteins and chromatin accessibility using PHAGE-ATACNat Biotechnol. 2022

Ochsenreither S, Fiedler WM, Conte GD,(...) Klinghammer KF, (...) Baumeister H, Zurlo A, Garralda E.: Safety and preliminary activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab in patients with refractory solid tumors. ESMO Open. 2022

Bastian L, Hartmann AM, Beder T, (...) Schwartz S, (...) Gökbuget N, Brüggemann M, Baldus CD.: UBTF::ATXN7L3 gene fusion defines novel B cell precursor ALL subtype with CDX2 expression and need for intensified treatmentLeukemia. 2022 

Klatt MG, Dao T, Yang Z, (...) Kharas MG, Liu C, Scheinberg DA: A TCR Mimic CAR T Cell Specific for NDC80 Is Broadly Reactive With Solid Tumors and Hematological MalignanciesBlood. 2022 

Grunert C, Willimsky G, Peuker CA, (...) Keller U, Pezzutto A, Busse A.: Isolation of Neoantigen-Specific Human T Cell Receptors from Different Human and Murine Repertoires. Cancers (Basel). 2022 

Demel UM, Lutz R, Sujer S, (...) Uckelmann HJ, Haas S, Essers M.: A complex proinflammatory cascade mediates the activation of HSCs upon LPS exposure in vivo. Blood Adv. 2022

Orben F, Lankes K, Schneeweis C, (...) Wirth M, Reichert M, Saur D, Schneider G.: Epigenetic drug screening defines a PRMT5 inhibitor sensitive pancreatic cancer subtypeJCI Insight. 2022

Trumpp A, Haas S.: Cancer stem cells: The adventurous journey from hematopoietic to leukemic stem cells. Cell. 2022  

Waguespack SG, Drilon A, Lin JJ, (...) Leyvraz S, (...) Brega N, Hong DS, Cabanillas ME.: Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinomaEur J Endocrinol. 2022

Ludwig LS, Lareau CA, Bao EL, (...) McCavit TL, Kanno H, Sankaran VG.: Congenital anemia reveals distinct targeting mechanisms for master transcription factor GATA1. Blood. 2022

Chandran SS, Ma J, Klatt MG, (...) Scheinberg DA, Baker BM, Klebanoff CA.: Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. Nat Med. 2022

Demel UM, Böger M, Yousefian S, Grunert C, Zhang L, (...) Köse H, Isaakidis K, (...) Rohleder E, (...) Baumgartner F, Habringer S, (...)  Chapuy B, (...) Haas S, Busse AB, Müller S, Wirth M, Schick M, Keller U: Activated SUMOylation restricts MHC class I antigen presentation to confer immune evasion in cancerJ Clin Invest. 2022

Jayavelu AK, Wolf S, Buettner F, (...) Chapuy B, (...) Serve H, Mann M, Oellerich T: The proteogenomic subtypes of acute myeloid leukemiaCancer Cell. 2022

Dao T, Mun S, Korontsvit T, (...) Klatt MG, Andrew D, Lorenz IC, Scheinberg DA: A TCR mimic monoclonal antibody for the HPV-16 E7-epitope p11-19/HLA-A*02:01 complex. PLoS One. 2022

Hernández-Malmierca P, Vonficht D, Schnell A, (...) Trumpp A, Kuchroo VK, Haas S: Antigen presentation safeguards the integrity of the hematopoietic stem cell poolCell Stem Cell. 2022

Lopez C, Schleussner N, Bernhart SH, (...) Janz M, (...) Schlesner M, Mathas S, Siebert R: Focal structural variants revealed by whole genome sequencing disrupt the histone demethylase KDM4C in B cell lymphomasHaematologica 2022

Bourne CM, Mun SS, Dao T, (...) Steidl C, Klatt MG, Scheinberg DA.: Unmasking the suppressed immunopeptidome of EZH2 mutated diffuse large B-cell lymphomas with combination drug treatment. Blood Adv. 2022

Leyvraz S, Konietschke F, Peuker C, (...) Ochsenreither S, (...) Lamping M, Rieke DT, Klinghammer K, Burock S, (...) Joussen A, Yaspo ML, Keilholz U.: Biomarker-driven therapies for metastatic uveal melanoma: A prospective precision oncology feasibility studyEur J Cancer. 2022

Hasan AN, Doubrovina E, Sottile R, (...) Klatt MG, (...) Barnett L, Hsu KC, O'Reilly RJ.: Dominant epitopes presented by prevalent HLA alleles permit wide use of banked CMVpp65 T-cells in adoptive therapy. Blood Adv. 2022 

Dreyling M, André M, Gökbuget N, (...) Chapuy B, (...) Trappe RU, Trümper LH, Salles G.: The EHA Research Roadmap: Malignant Lymphoid DiseasesHemasphere. 2022

Platzbecker U, Chromik J, Krönke J, (...) Tachibana Y, Taube T, Germing U.: Volasertib as a monotherapy or in combination with azacitidine in patients with myelodysplastic syndrome, chronic myelomonocytic leukemia, or acute myeloid leukemia: summary of three phase I studiesBMC Cancer. 2022

Ferreri AJM, Cwynarski K, Pulczynski E, (...) Keller U, (...) Zucca E, Illerhaus G; IELSG32 study investigators.: Long-term efficacy, safety and neurotolerability of MATRix regimen followed by autologous transplant in primary CNS lymphoma: 7-year results of the IELSG32 randomized trial. Leukemia. 2022

Krysiak K, Danos AM, Kiwala S, (...), Rieke DT, (...) Wagner AH, Griffith OL, Griffith M.: A community approach to the cancer-variant-interpretation bottleneck. Nat Cancer. 2022 

Grüne B, Meesters S, Bausewein C, Schildmann E.: Challenges and Strategies Regarding Sedation at the End of Life in Hospitals and Nursing HomesJ Pain Symptom Manage. 2022

Kremling A, Bausewein C, Klein C, Schildmann E, Ostgathe C, Ziegler K, Schildmann J.: Intentional Sedation as a Means to Ease Suffering: A Systematically Constructed Terminology for Sedation in Palliative CareJ Palliat Med. 2022

Kurkowski S, Heckel M, Pfaller L, Peters J, Bazata J, Schildmann E, Ostgathe C.: Possible age-related differences in healthcare professionals' perspectives on younger and older patients' autonomy and decision-making in the context of sedation in specialised palliative care: exploratory secondary qualitative content and linguistic conversation analysis of interviews with healthcare professionalsBMC Palliat Care. 2022

Hegazy AN, Krönke J, Angermair S, Schwartz S, (...), Keller U, Treskatsch S, Siegmund B, Schneider T.: Anti-SARS-CoV2 antibody-mediated cytokine release syndrome in a patient with acute promyelocytic leukemia. BMC Infect Dis. 2022 

Nguyen-Hoai T, Hohn O, Pezzutto A, Westermann J.: Gene Gun Her2/neu DNA Vaccination: Evaluation of Vaccine Efficacy in a Syngeneic Her2/neu Mouse Tumor Model. Methods Mol Biol. 2022

Heynen GJJE, Baumgartner F, Heider M, (...) Holz M, Braune J, Kaiser M, (...), Bamopoulos SA, Ramberger E, Murgai A, Ng YLD, Demel UM, Laue D, Liebig S, Krüger J, Janz M, Nogai A, Schick M, Mertins P, (...) Krönke J, Keller U, Wirth M.: SUMOylation inhibition overcomes proteasome inhibitor resistance in multiple myeloma. Blood Adv. 2022

Braitsch K, Schmalbrock LK, Jung P, (...) Keller U, (...) Krönke J, Götze KS, Rieger K.: Genotype and Intensive Pretreatment Influence Outcome of Acute Myeloid Leukemia Patients Treated With Venetoclax in Combination With Hypomethylating Agents or Low-dose Cytarabine: "Real World" Data From Germany.  Hemasphere. 2022

Machado HE, Mitchell E, Øbro NF, Kübler K, (...) Hodson DJ, Kent DG, Campbell PJ.: Diverse mutational landscapes in human lymphocytes. Nature. 2022

Kraus S, Klassen P, Kircher M, (...) Habringer S, (...) Keller U, Rasche L, Lapa C.: Reduced splenic uptake on 68Ga-Pentixafor-PET/CT imaging in multiple myeloma - a potential imaging biomarker for disease prognosis. Theranostics. 2022

Raffel S, Velten L, Haas S.: Cellular hierarchies predict drug response in acute myeloid leukemia. Cancer Cell. 2022 

Yang JCH, Brose MS, Castro G, (...) Leyvraz S, (...) Vassal G, Drilon A, Trent J.: Rationale and design of ON-TRK: a novel prospective non-interventional study in patients with TRK fusion cancer treated with larotrectinib. BMC Cancer. 2022

Garces de Los Fayos Alonso I, Zujo L, Wiest I, (...) Mathas S, (...) Moriggl R, Lagger S, Kenner L.: PDGFRβ promotes oncogenic progression via STAT3/STAT5 hyperactivation in anaplastic large cell lymphomaMol Cancer. 2022

Paulmann C, Spallek R, Karpiuk O, (...) Öllinger R, Engleitner T, Wirth M, Keller U, Krönke J, (...) Rad R, Kuster B, Bassermann F. The OTUD6B-LIN28B-MYC axis determines the proliferative state in multiple myeloma. EMBO J. 2022

Horak P, Griffith M, Danos AM, (...) Rieke D, (...) Griffith OL, Chakravarty D, Sonkin D.: Standards for the classification of pathogenicity of somatic variants in cancer (oncogenicity): Joint recommendations of Clinical Genome Resource (ClinGen), Cancer Genomics Consortium (CGC), and Variant Interpretation for Cancer Consortium (VICC). Genet Med. 2022

Condic M, Thiesler T, Staerk C, (...) Kübler K, Kristiansen G, Mustea A, Ralser DJ.: N6-methyladenosine RNA modification (m6A) is of prognostic value in HPV-dependent vulvar squamous cell carcinomaBMC Cancer. 2022

Demel UM, Wirth M, Yousefian S, Zhang L, Isaakidis K, (...) Böger M, Singh N, Köse H, Haas S, Müller S, Schick M, Keller U.: Small molecule SUMO inhibition for biomarker-informed B-cell lymphoma therapyHaematologica. 2022 

Evertz R, Gödde K, Diehl C, (...) Keller U, (...) Anker MS, Hasenfuß G, von Haehling S.: Cardiovascular and metabolic determinants of quality of life in patients with cancer. ESC Heart Fail. 2022

Carvajal RD, Butler MO, Shoushtari AN, (...) Leyvraz S, (...) Abdullah SE, Sacco JJ, Sato T.: Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trialNat Med. 2022

Rieke DT, de Bortoli T, Horak P, Lamping M, Benary M, Jelas I, Rüter G, Berger J, Zettwitz M, Kagelmann N, Kind A, Fabian F, Beule D, Glimm H, Brors B, Stenzinger A, Fröhling S, Keilholz U.: Feasibility and outcome of reproducible clinical interpretation of high-dimensional molecular data: a comparison of two molecular tumor boards. BMC Med. 2022

Rückert T, Lareau CA, Mashreghi MF, Ludwig LS, Romagnani C. Clonal expansion and epigenetic inheritance of long-lasting NK cell memory. Nat Immunol. 2022

Flumann R, Hansen J, Pelzer BW, (...) Chapuy B, (...) Melnick AM, Reinhardt HC, Knittel G.: Distinct genetically-determined origins of Myd88/Bcl2-driven aggressive lymphoma rationalize targeted therapeutic intervention strategies. Blood Cancer Discov. 2022

Krysiak K, Danos AM, Saliba J, (...) Rieke DT, (...) Wagner AH, Griffith M, Griffith OL.: CIViCdb 2022: evolution of an open-access cancer variant interpretation knowledgebase. Nucleic Acids Res. 2022

Hernández-Verdin I, Kirasic E, Wienand K, (...) Chapuy B, Hoang-Xuan K, Alentorn A.: Molecular and clinical diversity in primary central nervous system lymphoma. Ann Oncol. 2022

Hoffmeister-Wittmann P, Mock A, Nichetti F, (...) Ochsenreither S, (...) Goeppert B, Fröhling S, Köhler BC.: Bcl-xL as prognostic marker and potential therapeutic target in cholangiocarcinoma. Liver Int. 2022

Schildmann E, Meesters S, Grüne B, (...) Harbeck N, Hentrich M, Bausewein C: Sedatives and sedation at the end of life in the hospital—a multicenter retrospective cohort study. BMJ Support Palliat Care. 2022

Bergeron A, Mikulska M, De Greef J, (...) Maschmeyer G, Rovira M, Goletti D, de la Camara R; European Conference on Infections in Leukaemia group.: Mycobacterial infections in adults with haematological malignancies and haematopoietic stem cell transplants: guidelines from the 8th European Conference on Infections in Leukaemia. Lancet Infect Dis. 2022

Penter L, Ten Hacken E, Southard J, (...) Ludwig LS, (...) Neuberg DS, Livak KJ, Wu CJ.: Mitochondrial DNA mutations as natural barcodes for lineage tracing of murine tumor models. Cancer Res. 2022

Bröckelmann PJ, Bühnen I, Meissner J, (...) Mathas S, (...) Borchmann P, Engert A, von Tresckow B.: Nivolumab and Doxorubicin, Vinblastine, and Dacarbazine in Early-Stage Unfavorable Hodgkin Lymphoma: Final Analysis of the Randomized German Hodgkin Study Group Phase II NIVAHL Trial. J Clin Oncol. 2022

Vogel A, Ochsenreither S, Zager JS, Wacker F, Saborowski A.: Chemosaturation for primary and secondary liver malignancies: A comprehensive update of current evidence. Cancer Treat Rev. 2022

Braune J, Rieger K, Blau O, Keller U, Bullinger L, Krönke J.: Relapse of NPM1-Mutated AML with Extramedullary Manifestation 17 Years after Allogeneic Hematopoietic Stem Cell Transplantation. Case Rep Hematol. 2022


Mertens D, Krönke J.: Triggering T-cell activity in CLL.  Blood. 2021 

Wulf GG, Altmann B, Ziepert M, (...) Pezzutto A, (...) Schmitz N, Trümper L; ACT-2 study investigators.: Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.  Leukemia. 2021

Borchmann P, Plütschow A, Kobe C, (...) Keller K, (...) Diehl V, Dietlein M, Engert A.: PET-guided omission of radiotherapy in early-stage unfavourable Hodgkin lymphoma (GHSG HD17): a multicentre, open-label, randomised, phase 3 trial. Lancet Oncol. 2021

Mougiakakos D, Bach C, Böttcher M, (...) Krönke J, Mackensen A, Bruns H.: The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages. Cancer Immunol Res. 2021

Herda S, Heimann A, Obermayer B, (...) Busse A, (...) Pezzutto A, Blankenstein T, Beule D, Na IK.: Long-term in vitro expansion ensures increased yield of central memory T cells as perspective for manufacturing challenges. Int J Cancer. 2021

Alotaibi M, Valova V, HÄnsel T, (...) Ochsenreither S, Coordes A.: Impact of Smoking on the Survival of Patients With High-risk HPV-positive HNSCC: A Meta-analysis. In Vivo. 2021

Heider M, Eichner R, Stroh J, (...) Keller U, (...) Kuster B, Fernández-Sáiz V, Bassermann F.: The IMiD target CRBN determines HSP90 activity toward transmembrane proteins essential in multiple myeloma. Mol Cell. 2021

Frost N, Kollmeier J, Misch D, (...) Ochsenreither S, (...) Suttorp N, Witzenrath M, Grohé C.: Pembrolizumab as First-Line Palliative Therapy in PD-L1 Overexpressing (≥ 50%) NSCLC: Real-world Results with Special Focus on PS ≥ 2, Brain Metastases, and Steroids. Clin Lung Cancer. 2021

Schneeweis C, Hassan Z, Schick M, Keller U, Schneider G.: The SUMO pathway in pancreatic cancer: insights and inhibition. Br J Cancer. 2021

Rambaldi A, Iurlo A, Vannucchi AM, (...) Nogai A, (...) Bettica P, Manzoni S, Di Tollo S.: Long-term safety and efficacy of givinostat in polycythemia vera: 4-year mean follow up of three phase 1/2 studies and a compassionate use program. Blood Cancer J. 2021

Velten  L, Story BA, Hernández-Malmierca P, (...) Trumpp, M, Haas S, Steinmetz LM: Identification of leukemic and pre-leukemic stem cells by clonal tracking from single-cell transcriptomics.  Nat Commun. 2021

Yao W, Qian X, Ochsenreither S, (...) Klinghammer K, Kaufmann AM, Albers AE.: Disulfiram Acts as a Potent Radio-Chemo Sensitizer in Head and Neck Squamous Cell Carcinoma Cell Lines and Transplanted Xenografts. Cells. 2021

Boeker R, Stromberger C, Heiland M, (...) Ochsenreither S, (...) Dommerich S, Piwonski I, Coordes A.: Carcinoma of Unknown Primary and the 8th Edition TNM Classification for Head and Neck Cancer.
Laryngoscope. 2021  

Frost N, Kollmeier J, Vollbrecht C, (...) Ochsenreither S, (...) Suttorp N, Witzenrath M, Grohé C.: KRASG12C/TP53 co-mutations identify long-term responders to first line palliative treatment with pembrolizumab monotherapy in PD-L1 high (≥50%) lung adenocarcinoma. Transl Lung Cancer Res. 2021  

Panagiota V, Meggendorfer M, Kubasch AS, (...) Krönke J, (...) Haferlach T, Platzbecker U, Heuser M.: Impact of PPM1D Mutations in Patients with Myelodysplastic Syndrome and Deletion of Chromosome 5q. Am J Hematol. 2021

Schmalbrock LK, (...) Döhner H, Döhner K, Bullinger L.: Clonal evolution of acute myeloid leukemia with FLT3-ITD mutation under treatment with midostaurin. Blood. 2021

Pohl J, Mincu RI, Mrotzek SM, (...) Keller U, (...) Rassaf T, Anker MS, Totzeck M.: ECG Scoring for the Evaluation of Therapy-Naïve Cancer Patients to Predict Cardiotoxicity. Cancers (Basel). 2021

Obenaus M, Schildgen O, Schürmann D, (...) Janz M, Keller U, (...) Schwartz S, Weissbrich B, Schneider T, Hofmann J, Mathas S.: High-dose glucocorticoid treatment of near-fatal bocavirus lung infection results in rapid recovery. ERJ Open Res. 2021

Kittner M, Lamping M, Rieke DT, (...) Malek NP, Keilholz U, Leser U.: Annotation and initial evaluation of a large annotated German oncological corpus. JAMIA Open. 2021

Bohl SR, Schmalbrock LK, (...) Damm F, Heckl D, Bullinger L, Krönke J.: Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma. Blood Adv. 2021

Rogasch JMM, Frost N, Bluemel S, (...) Ochsenreither S, Böhmer D, Amthauer H, Furth C.: FDG-PET/CT for pretherapeutic lymph node staging in non-small cell lung cancer: A tailored approach to the ESTS/ESMO guideline workflow. Lung Cancer. 2021

Albrecht A, Porthun J, Eucker J, (...) Pezzutto A, (...) Keller U, (...) Haverkamp W, Anker SD, Anker MS.: Spontaneous Non-Sustained Ventricular Tachycardia and Premature Ventricular Contractions and Their Prognostic Relevance in Patients with Cancer in Routine Care. Cancers (Basel). 2021

Bohl SR, Schmalbrock LK, (...) Krönke J.: Comprehensive CRISPR-Cas9 screens identify genetic determinants of drug responsiveness in multiple myeloma. Blood Adv. 2021

Kreissl S, Goergen H, Buehnen I, (...) Keller UB, (..) Engert A, Borchmann P; German Hodgkin Study Group.: PET-guided eBEACOPP treatment of advanced-stage Hodgkin lymphoma (HD18): follow-up analysis of an international, open-label, randomised, phase 3 trial. Lancet Haematol. 2021

Kayser S, Schlenk RF, Lebon D, (...) Keller U, (...) Fenaux P, Platzbecker U, Adès L.: Characteristics and outcome of patients with low-/intermediate-risk acute promyelocytic leukemia treated with arsenic trioxide - an international collaborative study. Haematologica. 2021

Haertle L, Barrio S, Munawar U, (...) Krönke J, (...) Martinez-Lopez J, Haaf T, Kortüm KM.: Cereblon Enhancer Methylation and IMiD Resistance in Multiple Myeloma. Blood. 2021

Panagiota V, Meggendorfer M, Kubasch AS, (...) Krönke J, (...) Haferlach T, Platzbecker U, Heuser M.: Impact of PPM1D mutations in patients with myelodysplastic syndrome and deletion of chromosome 5q. Am J Hematol. 2021

Lüftner D, Tesch H, Schmidt M, (...) Rosé C, Valenti R, Harbeck N: Neratinib as extended adjuvant therapy in patients with copositive early breast cancer: German health technology assessment-driven analyses from the ExteNET study. Eur J Cancer. 2021

Reinert J, Beitzen-Heineke A, Wethmar K, (...) Schwartz S.: Loss of CD22 expression and expansion of a CD22dim subpopulation in adults with relapsed/refractory B-lymphoblastic leukaemia after treatment with Inotuzumab-Ozogamicin. Ann Hematol. 2021

Janjetovic S, Lohneis P, Nogai A, (...) Schilling G, Blau IW, Schmidt-Hieber M.: Clinical and Biological Characteristics of Medullary and Extramedullary Plasma Cell Dyscrasias. Biology (Basel). 2021

Çınar Ö, Brzezicha B, Grunert C, (...) Peuker CA, Keller U, Pezzutto A, Busse A.: High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies. J Immunother Cancer. 2021

Mougiakakos D, Bach C, Böttcher M, (...) Krönke J, Mackensen A, Bruns H.: The IKZF1-IRF4/IRF5 Axis Controls Polarization of Myeloma-Associated Macrophages. Cancer Immunol Res. 2021

Kröger N, Sockel K, Wolschke C, (...) Krönke J, (...) Bleckert G, Giagounidis A, Platzbecker U.: Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study). J Clin Oncol. 2021

Hein A, Hartkopf AD, Emons J, (...) Lüftner D, (...) Brucker SY, Schneeweiss A, Kolberg HC: Prognostic effect of low-level HER2 expression in patients with clinically negative HER2 status. Eur J Cancer. 2021

Liebers N, Duell J, Fitzgerald D, (...) Leng C, (...) Keller U, (...) Lenz G, Dreger P, Dietrich S: Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas. Blood Adv. 2021 Jul

Denker S, Bittner A, Frick M, (...) Keller U, Bogner C, Hüttmann A, Dürig J, Janz M, Mathas S, Marks R, Krohn U, Na IK.: Ibrutinib- and bortezomib-extended R-CHOP induction in elderly higher-risk patients newly diagnosed with diffuse large B-cell lymphoma - first analysis of toxicity and efficacy signals. Leuk Lymphoma. 2021

Damaschin C, Goergen H, Kreissl S, (...) Mathas S, (...) Engert A, Borchmann P, Eichenauer DA.: Brentuximab vedotin-containing escalated BEACOPP variants for newly diagnosed advanced-stage classical Hodgkin lymphoma: follow-up analysis of a randomized phase II study from the German Hodgkin Study Group. Leukemia. 2021

Young K, Eudy E, Bell R, (...) Haas S, Filippi MD, Trowbridge JJ: Decline in IGF1 in the bone marrow microenvironment initiates hematopoietic stem cell aging. Cell Stem Cell. 2021

Lewis R, Habringer S, Kircher M, Hefter M, Peuker CA, Werner R, Ademaj-Kospiri V, (...) Keller U.: Investigation of spleen CXCR4 expression by [68Ga]Pentixafor PET in a cohort of 145 solid cancer patients. EJNMMI Res. 2021

Lewis R, (...) Wirth M, Schick M, Zhang L, Isaakidis K, (...) Schulze V, (...) Keller U, Habringer S.: CXCR4 hyperactivation cooperates with TCL1 in CLL development and aggressiveness. Leukemia. 2021

Herda S, Heimann A, Obermayer B, (...) C, Busse A, Bullinger L, Pezzutto A, Blankenstein T, Beule D, Na IK.: Long-term in vitro expansion ensures increased yield of central memory T cells as perspective for manufacturing challenges. Int J Cancer. 2021

Schettini F, Giuliano M, Lambertini M, (...) Lüftner D, (...) Venturini S, Curigliano G, Generali D.: Anthracyclines Strike Back: Rediscovering Non-Pegylated Liposomal Doxorubicin in Current Therapeutic Scenarios of Breast Cancer. Cancers (Basel). 2021

Klinghammer K, (...) Ochsenreither S, Keilholz U.: A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck - the RESGEX study. ESMO Open. 2021

Nathan P, Hassel JC, Rutkowski P, (...) Ochsenreither S, (...) Holland C, Goodall H, Piperno-Neumann S: Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2021

Yap TA, Vieito M, Baldini C, (...) Ochsenreither S, (...) Gandhi L, Avsar E, Melisi D.: First-In-Human Phase I Study of a Next-Generation, Oral, Transforming Growth Factor-Beta Receptor 1 Inhibitor, LY3200882 in Patients with Advanced Cancer. Clin Cancer Res. 2021

Liang HC, Costanza M, (...) Silva DA, Garcia KC, Baker D, Janz M, (...) Mathas S, Kenner L, Merkel O.: Super-enhancer-based identification of a BATF3/IL-2R-module reveals vulnerabilities in anaplastic large cell lymphoma. Nat Commun. 2021 

Witzens-Harig M, Viardot A, Keller U, (...) Buske C, Dreyling MH, Hess G.: The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL - Results From the Phase-II STORM Trial. Hemasphere. 2021

Heck C, Steiner S, Kaebisch EM, (...) Nogai A, (...) Bullinger L, Blau IW, Na IK.: CD4+ T Cell Dependent B Cell Recovery and Function After Autologous Hematopoietic Stem Cell Transplantation. Front Immunol. 2021

Schneider G, Wirth M, Keller U, Saur D.: Rationale for MYC imaging and targeting in pancreatic cancer. EJNMMI Res. 2021

Kaddu-Mulindwa D, Lesan V, Berdel C, (...) Keller U, (...) Poeschel V, Held G, Jagoda P.: Significant reduced loss of bone mineral density after four vs. six cycles of R-CHOP: an analysis of the FLYER-trial. Leuk Lymphoma. 2021 

Bricelj A, Dora Ng YL, (...) Krönke J, Sosič I, Gütschow M, Steinebach C.: Influence of Linker Attachment Points on the Stability and Neosubstrate Degradation of Cereblon Ligands. ACS Med Chem Lett. 2021

Mimitou EP, Lareau CA, Chen KY, (...) Ludwig LS, Sankaran VG, Regev A, Smibert P.: Scalable, multimodal profiling of chromatin accessibility, gene expression and protein levels in single cells. Nat Biotechnol. 2021 

Heilig CE, Horak P, Kreutzfeldt S, (...) Ochsenreither S, (...) Glimm H, Fröhling S, Schlenk RF.: Rationale and design of the CRAFT (Continuous ReAssessment with Flexible ExTension in Rare Malignancies) multicenter phase II trial. ESMO Open. 2021

Triana S, Vonficht D, Jopp-Saile L, (...) Paulsen M, Velten L, Haas S.: Single-cell proteo-genomic reference maps of the hematopoietic system enable the purification and massive profiling of precisely defined cell states. Nat Immunol. 2021 

Thobe K, Konrath F, Chapuy B, Wolf J.: Patient-Specific Modeling of Diffuse Large B-Cell Lymphoma. Biomedicines. 2021

Bishop MR, Dickinson M, Purtill D, (...) Janz M, (...) Jäger U, Borchmann P, Westin JR.: Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma. N Engl J Med. 2021

Kröger N, Sockel K, Wolschke C, (...) Krönke J, (...) Bleckert G, Giagounidis A, Platzbecker U.: Comparison Between 5-Azacytidine Treatment and Allogeneic Stem-Cell Transplantation in Elderly Patients With Advanced MDS According to Donor Availability (VidazaAllo Study). J Clin Oncol. 2021

Haertle L, Barrio S, Munawar U, (...) Krönke J, (...) Martinez-Lopez J, Haaf T, Kortüm KM.: Cereblon enhancer methylation and IMiD resistance in multiple myeloma. Blood. 2021

Goerling U, Gauler T, Dietz A, (...) Knödler M, Keilholz U, Klinghammer K.: Quality of Life of Patients with Head and Neck Cancer Receiving Cetuximab, Fluorouracil, Cisplatin Comparing to Cetuximab, Fluorouracil, Cisplatin and Docetaxel within the CEFCID Trial. Oncol Res Treat. 2021

Peuker CA, Yaghobramzi S, Grunert C, (...), Gjerga E, (...) Keller U, (...) Schuler M, Lüftner D, Busse A.: Treatment with ribociclib shows favourable immunomodulatory effects in patients with hormone receptor-positive breast cancer-findings from the RIBECCA trial. Eur J Cancer. 2021

Çınar Ö, Brzezicha B, Grunert C, Kloetzel PM, Beier C, Peuker CA, Keller U, Pezzutto A, Busse A.: High-affinity T-cell receptor specific for MyD88 L265P mutation for adoptive T-cell therapy of B-cell malignancies. J Immunother Cancer. 2021

Tu M, Klein L, Espinet E, (...) Chapuy B, (...) Papantonis A, Ellenrieder V, Singh SK. TNF-α-producing macrophages determine subtype identity and prognosis via AP1 enhancer reprogramming in pancreatic cancer. Nat Cancer. 2021

Krauß L, Urban BC, Hastreiter S, (...) Wirth M, (...) Schotta G, Saur D, Schneider G.: HDAC2 facilitates pancreatic cancer metastasis. Cancer Res. 2021

Szydłowski M, Garbicz F, Jabłońska E, (...) Havranek O, Chapuy B, Juszczyński P.: Inhibition of PIM Kinases in DLBCL Targets MYC Transcriptional Program and Augments the Efficacy of Anti-CD20 Antibodies. Cancer Res. 2021





Kroschinsky F, Middeke JM, Janz M (...) Burkard U, Berk A, Schmitz N.: Phase I dose escalation study of BI 836826 (CD37 antibody) in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. Invest New Drugs. 2020

Teck AT, Urban S, Quass P, (...) Letsch A, Busse A, Walz JS, Keilholz U, Ochsenreither S.: Cancer testis antigen Cyclin A1 harbors several HLA-A*02:01-restricted T cell epitopes, which are presented and recognized in vivo. Cancer Immunol Immunother. 2020

Biederstädt, A., Hassan, Z., Schneeweis, C., Schick, M., (...) Wirth, M., (...) Reichert, M., Schneider, G., Keller, U.: SUMO pathway inhibition targets an aggressive pancreatic cancer subtype. Gut. 2020

Jesinghaus, M., Steiger, K., Stögbauer, F. (...) Wirth, M. (...), Klinghammer, K. (...) Combs, S.E., Weichert, W., Boxberg, M.: Pre-operative cellular dissociation grading in biopsies is highly predictive of post-operative tumour stage and patient outcome in head and neck squamous cell carcinoma. Br J Cancer. 2020

Poeschel V, Held, G, Ziepert M, (...) Keller U, (...) Loeffler M, Pfreundschuh M; FLYER Trial Investigators; German Lymphoma Alliance.:  Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial.  Lancet. 2020

Rambaldi A, Iurlo A, Vannucchi AM, (...) Pezzutto A, (...), Bettica P, Manzoni S, Di Tollo S.: Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study. Leukemia. 2020

Lamping M, Benary M, Leyvraz S, (...) Klinghammer K, Ochsenreither S, (...) Yaspo ML, Keilholz U, Rieke DT.: Support of a molecular tumour board by an evidence-based decision management system for precision oncology.  Eur J Cancer. 2020

Mylonas E, Yoshida K, Frick M, (...) Obenaus M, (...) Rose-Zerilli MJJ, Ogawa S, Damm F.:  Single-cell analysis based dissection of clonality in myelofibrosis.  Nat Commun. 2020

Ruhnke M, Cornely OA, Schmidt-Hieber M, (...), von Lilienfeld-Toal M, Weissinger F, Schwartz S.: Treatment of invasive fungal diseases in cancer patients - Revised 2019 Recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and Oncology (DGHO). Mycoses. 2020

Topp MS, Duell J, Zugmaier G, (...) Krönke J, (...) Minella AC, Munzert G, Einsele H.: Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma.  J Clin Oncol. 2020

Wagner AH, Walsh B, Mayfield G, (...) Rieke DT, (...) Griffith OL, Margolin AA; Variant Interpretation for Cancer Consortium.: A harmonized meta-knowledgebase of clinical interpretations of somatic genomic variants in cancer.  Nat Genet. 2020

Rohrmoser A, Pichler T, Letsch A (...) Keilholz U (...) Heinemann V, Westphalen CB, Goerling U.: Cancer patients´ expectations when undergoing extensive molecular diagnostics-A qualitative study: Psychooncology. 2020

Thomssen C, Lüftner D (...) Schwoerer M, Steinfeld-Birg D, Ziegler-Löhr K: International Consensus Conference for Advanced Breast Cancer, Lisbon 2019: ABC5 Consensus - Assessment by a German Group of Experts. Breast Care (Basel). 2020

Schneeweiss A, Hartkopf AD, Müller V (...) Lüftner D, Schütz F: Update Breast Cancer 2020 Part 1 - Early Breast Cancer: Consolidation of Knowledge About Known Therapies. Geburtshilfe Frauenheilkd. 2020

Lüftner D, (...) Schneeweiss A, Hartkopf AD, Müller V: Update Breast Cancer 2020 Part 2 - Advanced Breast Cancer: New Treatments and Implementation of Therapies with Companion Diagnostics. Geburtshilfe Frauenheilkd. 2020

Herhaus P, Lipkova J, Lammer F, (...) Habringer S, (...) Weber WA, Menze B, Keller U.: CXCR4-targeted positron emission tomography imaging of central nervous system B-cell lymphoma. J Nucl Med. 2020

Bröckelmann PJ, Goergen H, Keller U, (...) Mathas S, (...) Kobe C, Borchmann P, Engert A.: Efficacy of Nivolumab and AVD in Early-Stage Unfavorable Classic Hodgkin Lymphoma: The Randomized Phase 2 German Hodgkin Study Group NIVAHL Trial. JAMA Oncol. 2020

Toews K, Grunewald L, Schwiebert S, (...) Ochsenreither S, Eggert A, Künkele A.: Central memory phenotype drives success of checkpoint inhibition in combination with CAR T cells. Mol Carcinog. 2020

Bamopoulos SA, Batcha AMN, Jurinovic V (...), Spiekermann K, Metzeler KH, Herold T: Clinical presentation and differential splicing of SRSF2, U2AF1 and SF3B1 mutations in patients with acute myeloid leukemia. Leukemia. 2020

Opatz S, Bamopoulos SA, Metzeler KH, (...) Spiekermann K, Bohlander SK, Greif PA: The clinical mutatome of core binding factor leukemia. Leukemia. 2020

Raab MS, Engelhardt M, Blank A (...) Blau IW (...) Jarutat T, Peschel C, Chatterjee M: MOR202, a novel anti-CD38 monoclonal antibody, in patients with relapsed or refractory multiple myeloma: a first-in-human, multicentre, phase 1-2a trial. Haematol. 2020

Goldschmidt H, Mai EK, Dürig J (...) Blau IW ( ...) Raab MS, Hänel M, Salwender HJ: German-speaking Myeloma Multicenter Group (GMMG): Response-adapted lenalidomide maintenance in newly diagnosed myeloma: results from the phase III GMMG-MM5 trial. Leukemia. 2020

Kiefer T, Krahl D, Kohlmann T, Nogai A (...) Völler H, Buhlert H, Daeschlein G: Does rehabilitation pose a risk to patients suffering from haemato-oncological diseases?. Eur J Cancer Care. 2020

Wulf GG, Altmann B, Ziepert M, (...) Pezzutto A, (...) Schmitz N, Trümper L: ACT-2 study investigators: Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial.  Leukemia. 2020

Toboso-Navasa A, Gunawan A, Morlino G, (...) Janz M, (...) Brink R, Eilers M, Calado DP: Restriction of memory B cell differentiation at the germinal center B cell positive selection stage. J Exp Med. 2020

Messerschmidt C, Obermayer B, Klinghammer K, Ochsenreither S, (...) Keilholz U, Beule D, Rieke DT: Distinct immune evasion in APOBEC-enriched, HPV-negative HNSCC. Int J Cancer. 2020

Kiweler N, Wünsch D, Wirth M, (...) Brenner W, Butter F, Krämer OH: Histone deacetylase inhibitors dysregulate DNA repair proteins and antagonize metastasis-associated processes J Cancer Res Clin Oncol. 2020

Hess G, Wagner K, Keller U, (...); Klapper W, Theobald M, Dreyling M: Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma.  HemaSphere. 2020

Oing C, Hentrich M, Lorch A, (...) Ochsenreither S, (...) Pereira RR, Bokemeyer C, Seidel C. Treatment of refractory germ-cell tumours with single-agent cabazitaxel: a German Testicular Cancer Study Group case series. J Cancer Res Clin Oncol. 2020

Rogasch JMM, Furth C, Chibolela C, (...) Ochsenreither S, (...) von Laffert M, Amthauer H: Frost N. Validation of Independent Prognostic Value of Asphericity of 18F-Fluorodeoxyglucose Uptake in Non-Small-Cell Lung Cancer Patients Undergoing Treatment With Curative Intent. Clin Lung Cancer. 2020

Delgado-Benito V, Berruezo-Llacuna M, Altwasser R, (...) Janz M, Akalin A, Di Virgilio M: PDGFA-associated protein 1 protects mature B lymphocytes from stress-induced cell death and promotes antibody gene diversification. J Exp Med. 2020

Frost N, Zhamurashvili T, von Laffert M, (...) Ochsenreither S, (...) Suttorp N, Grohé C, Witzenrath M: Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis. Clin Lung Cancer. 2020

Goldschmidt H, Baertsch MA, Schlenzka J, (...) Nogai A, (...) Besemer B, Weisel K; German Myeloma Multicenter Group (GMMG): Salvage autologous transplant and lenalidomide maintenance vs. lenalidomide/dexamethasone for relapsed multiple myeloma: the randomized GMMG phase III trial ReLApsE. Leukemia. 2020

Tinhofer I, Braunholz D, Klinghammer K: Preclinical models of head and neck squamous cell carcinoma for a basic understanding of cancer biology and its translation into efficient therapies. Cancers Head Neck. 2020

Pouyiourou M, Meyer A, Stroux A, (...) Keller U, (...) Herold M, Scholz CW; East German Study Group for Hematology and Oncology (OSHO): First-line treatment with R-CHOP or rituximab-bendamustine in patients with follicular lymphoma grade 3A-results of a retrospective analysis. Ann Hematol. 2020

Hess G, Wagner K, Keller U, (...) Klapper W, Theobald M, Dreyling M.: Final Results of a Phase I/II Trial of the Combination Bendamustine and Rituximab With Temsirolimus (BeRT) in Relapsed Mantle Cell Lymphoma and Follicular Lymphoma. Hemasphere. 2020

Lüftner D, Lyman GH, Gonçalves J, Pivot X, Seo M.: Biologic Drug Quality Assurance to Optimize HER2 + Breast Cancer Treatment: Insights from Development of the Trastuzumab Biosimilar SB3. Target Oncol. 2020

Meyer T, Jahn N, Lindner S, (...) Bullinger L, Döhner K, Krönke J.: Functional characterization of BRCC3 mutations in acute myeloid leukemia with t(8;21)(q22;q22.1). Leukemia. 2020

Gronbach L, Wolff C, Klinghammer K, (...) Tinhofer I, Keilholz U, Zoschke C.: A multilayered epithelial mucosa model of head neck squamous cell carcinoma for analysis of tumor-microenvironment interactions and drug development. Biomaterials. 2020

Kapp-Schwoerer S, Weber D, Corbacioglu A, (...) Krönke J, (...) Ganser A, Döhner H, Döhner K.: Impact of gemtuzumab ozogamicin on MRD and relapse risk in NPM1 mutated AML patients: results from the AMLSG 09-09 Trial. Blood. 2020

Kim D, Elgeti T, Penzkofer T, (...) Schwartz S, Hamm B, Nagel SN: Enhancing the differentiation of pulmonary lymphoma and fungal pneumonia in hematological patients using texture analysis in 3-T MRI. Eur Radiol. 2020

Mrotzek SM, Lena A, Hadzibegovic S, (...) Keller U, (...) Rassaf T, Anker MS, Totzeck M: Assessment of coronary artery disease during hospitalization for cancer treatment. Clin Res Cardiol. 2020

Kubasch AS, Schulze F, Giagounidis A, (...) Krönke J, (...) Adès L, Oelschlägel U, Platzbecker U: Single agent talacotuzumab demonstrates limited efficacy but considerable toxicity in elderly high-risk MDS or AML patients failing hypomethylating agents. Leukemia. 2020

Pichler T, Rohrmoser A, Letsch A, (...) Keilholz U, (...) Lamping M, (...) Riedmann K, Herschbach P, Goerling U: Information, communication, and cancer patients' trust in the physician: what challenges do we have to face in an era of precision cancer medicine? Support Care Cancer. 2020

Hermann M, Kühne F, Rohrmoser A, (...) Letsch A: Perspectives of patients with multiple myeloma on accepting their prognosis-A qualitative interview study. Psychooncology. 2020

Dantes Z, Yen HY, Pfarr N, (...) Wirth M, (...) Schmid RM, Schneider G, Reichert M: Implementing cell-free DNA of pancreatic cancer patient-derived organoids for personalized oncology. JCI Insight. 2020

Scholz F, Grau M, Menzel L, (...) Janz M, Lenz G, Rehm A, Höpken UE: The transcription factor C/EBPβ orchestrates dendritic cell maturation and functionality under homeostatic and malignant conditions. Proc Natl Acad Sci U S A. 2020

Voltin CA, Mettler J, van Heek L, (...) Keller U, (...) Engert A, Kobe C, Bröckelmann PJ: Early Response to First-Line Anti-PD-1 Treatment in Hodgkin Lymphoma: A PET-Based Analysis from the Prospective, Randomized Phase II NIVAHL Trial. Clin Cancer Res. 2020

Reinke S, Bröckelmann PJ, Iaccarino I, (...) Mathas S., (...) Keller U, (...) Rosenwald A, Engert A, Klapper W: Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1. Blood. 2020

Klinghammer K, Politz O, Eder T, Otto R, (...) Keller U, Keilholz U: Combination of copanlisib with cetuximab improves tumor response in cetuximab-resistant patient-derived xenografts of head and neck cancer. Oncotarget. 2020

Steinebach C, Ng YLD, Sosič I, (...) Luo J, Gütschow M, Krönke J.: Systematic exploration of different E3 ubiquitin ligases: an approach towards potent and selective CDK6 degraders. Chem Sci. 2020

Rambaldi A, Iurlo A, Vannucchi AM, (...) Pezzutto A, (...) Bettica P, Manzoni S, Di Tollo S.: Safety and efficacy of the maximum tolerated dose of givinostat in polycythemia vera: a two-part Phase Ib/II study. Leukemia. 2020

Rieke DT, Keller U.: A CD205-directed antibody drug conjugate - lymphoma precision oncology or sophisticated chemotherapy? Haematologica. 2020

Röhner L, Ng YLD, Scheffold A, (...), Krönke J.: Generation of a lenalidomide-sensitive syngeneic murine in vivo multiple myeloma model by expression of CrbnI391V. Exp Hematol. 2020

Reimann M, Schrezenmeier JF, Richter-Pechanska P, (...) Busse A, (...) Rosenwald A, Reinhardt HC, Schmitt CA.: Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas. Blood. 2020

Busse A, Mochmann LH, Spenke C, (...) Briest F, (...) Kaemmerer D, Baum RP, Grabowski P.: Immunoprofiling in Neuroendocrine Neoplasms Unveil Immunosuppressive Microenvironment. Cancers (Basel). 2020

Abi Habib J, De Plaen E, Stroobant V, (...) Busse A, Vigneron N, Van den Eynde BJ.: Efficiency of the four proteasome subtypes to degrade ubiquitinated or oxidized proteins. Sci Rep. 2020

Wirth M, Schick M, Keller U, Krönke J.: Ubiquitination and Ubiquitin-Like Modifications in Multiple Myeloma: Biology and Therapy. Cancers (Basel). 2020

Topp MS, Duell J, Zugmaier G, (...) Krönke J, (...) Minella AC, Munzert G, Einsele H.: Anti-B-Cell Maturation Antigen BiTE Molecule AMG 420 Induces Responses in Multiple Myeloma. J Clin Oncol. 2020 

Hong Y, Singh N, Bamopoulos S, Gjerga E, Schmalbrock LK, Balabanian K, Schick M, Keller U, Wirth M.: Authentication of Primary Murine Cell Lines by a Microfluidics-Based Lab-On-Chip System. Biomedicines. 2020

Schmitz N, Truemper L, Bouabdallah K, (...) Keller K, (...) Nickelsen M, Altmann B, Tournilhac O.: A randomized phase 3 trial of auto vs. allo transplantation as part of first-line therapy in poor-risk peripheral T-NHL. Blood. 2020

Anker M, von Haehling S, Coats A, (...) Eucker J, (...) Haverkamp W, Landmesser U, Anker S.: Ventricular tachycardia, premature ventricular contractions, and mortality in unselected patients with lung, colon, or pancreatic cancer: a prospective study. Eur J Heart Fail. 2020

Kapp-Schwoerer S, Weber D, Corbacioglu A, (...) Krönke J, (...) Ganser A, Döhner H, Döhner K.: Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with NPM1-mutated AML: results from the AMLSG 09-09 trial. Blood. 2020


Scherger, A.K., Al-Maarri, M., Maurer, H.C., (...), Wunderlich, F.T., Rose-John, S., Keller, U.: Activated gp130 signaling selectively targets B cell differentiation to induce mature lymphoma and plasmacytoma. JCI Insight. 2019;4.

Hüllein, J., Słabicki, M., Rosolowski, M., (...) Keller, U., Huber, W., Zenz, T.: MDM4 Is Targeted by 1q Gain and Drives Disease in Burkitt Lymphoma. Cancer Res. 2019;79:3125-38.

Weber, J., de la Rosa, J., Grove, C.S., (...) Keller, U., Vassiliou, G.S., Cadiñanos, J., Bradley, A., Rad, R.: PiggyBac transposon tools for recessive screening identify B-cell lymphoma drivers in mice. Nat Commun. 2019;10:1415.

von Hoff, L., Kärgel, E., Franke, V., (...) Akalin, A., Mathas, S., Scheidereit, C.: Autocrine LTA signaling drives NF-κB and JAK-STAT activity and myeloid gene expression in Hodgkin lymphoma. Blood. 2019;133:1489-94.

Edginton-White, B., Cauchy, P., Assi, S.A., (...) Mathas, S., Cockerill, P.N., Bonifer, C.: Global long terminal repeat activation participates in establishing the unique gene expression programme of classical Hodgkin lymphoma. Leukemia. 2019;33:1463-74.

Storck, K., Brandstetter, M., Keller, U., Knopf, A.: Clinical presentation and characteristics of lymphoma in the head and neck region. Head Face Med. 2019;15(1):1.

O'Connor, T., Zhou, X., Kosla, J., (...) von Baumgarten, L., Keller, U., Heikenwalder, M.:Age-Related Gliosis Promotes Central Nervous System Lymphoma through CCL19-Mediated Tumor Cell Retention. Cancer Cell. 2019;36(3):250-267.

Fuchs, M., Goergen, H., Kobe, C., (...) Keller, UB., (...) Dietlein, M., Borchmann, P., Engert, A.: Positron Emission Tomography-Guided Treatment in Early-Stage Favorable Hodgkin Lymphoma: Final Results of the International, Randomized Phase III HD16 Trial by the German Hodgkin Study Group. J Clin Oncol. 2019:JCO1900964.

Schroeder, M.P., Bastian, L., Eckert, C., (...) Serve, H., Neumann, M., Baldus, C.D.: Integrated analysis of relapsed B-cell precursor Acute Lymphoblastic Leukemia identifies subtype-specific cytokine and metabolic signatures. Sci Rep. 2019;9:4188.

Bastian, L., Schroeder, M.P., Eckert, C., (...) Gökbuget, N., Neumann, M., Baldus, C.D.: PAX5 biallelic genomic alterations define a novel subgroup of B-cell precursor acute lymphoblastic leukemia. Leukemia. 2019.

James, A.R., Schroeder, M.P., Neumann, M., (...) Serve, H., Akalin, A., Baldus, C.D.: Long non-coding RNAs defining major subtypes of B cell precursor acute lymphoblastic leukemia. J Hematol Oncol. 2019;12:8.

Maurer, S., Herhaus, P., Lippenmeyer, R., (...) Grigoleit, G.U., Keller, U., Lapa, C.: Side effects of CXC-chemokine receptor 4 - directed Endoradiotherapy with Pentixather prior to Hematopoietic Stem Cell Transplantation. J Nucl Med. 2019.

Nimmagadda, S.C., Frey, S., Müller, P., (...) Keller, U., Edelmann, B., Fischer, T.: SDF1α-induced chemotaxis of JAK2-V617F-positive cells is dependent on Bruton tyrosine kinase and its downstream targets PI3K/AKT, PLCγ1 and RhoA. Haematologica. 2019;104:e288-92.

Curran, D., Matthews, S., Rowley, S.D., (...) Schwartz, S., (...) Yeh SP, Zaja F, Szer J; ZOE-HSCT Study group collaborators: Recombinant Zoster Vaccine Significantly Reduces the Impact on Quality of Life Caused by Herpes Zoster in Adult Autologous Hematopoietic Stem Cell Transplant Recipients: A Randomized Placebo-Controlled Trial (ZOE-HSCT). Biol Blood Marrow Transplant. 2019: S1083-8791(19)30508-7

Bastidas, A., de la Serna, J., El Idrissi, M., (...) Schwartz, S., (...) Stadtmauer, E.A., Sullivan, K.M.; ZOE-HSCT Study Group Collaborators: Effect of Recombinant Zoster Vaccine on Incidence of Herpes Zoster After Autologous Stem Cell Transplantation: A Randomized Clinical Trial. JAMA. 2019;322(2):123-133.

Wagner, K., Kunz, K., Piller, T., (...) Schick, M., Keller, U., Müller, S.: The SUMO Isopeptidase SENP6 Functions as a Rheostat of Chromatin Residency in Genome Maintenance and Chromosome Dynamics. Cell Rep. 2019;29(2):480-494

Lux, M.P., Böhme, S., Hücherig, S., Jeratsch, U., Kürschner, N., Lüftner, D.: Surrogate threshold effect based on a meta-analysis for the predictive value of progression-free survival for overall survival in hormone receptor-positive, HER2-negative metastatic breast cancer. Breast Cancer Res Treat. 2019;176:495-506.

Busse, A., Lüftner, D.: What Does the Pipeline Promise about Upcoming Biosimilar Antibodies in Oncology? Breast Care (Basel). 2019;14:10-6.
Lüftner, D.: Approval by Authorities Does Not Allow For Suboptimal Study Conduct but Offers New Academic Possibilities. Breast Care (Basel). 2019;14:2-3.

Preisler, M., Rohrmoser, A., Goerling, U., (...) Riemer, M., Heuse, S., Letsch, A.: Early palliative care for those who care: A qualitative exploration of cancer caregivers' information needs during hospital stays. Eur J Cancer Care (Engl). 2019;28:e12990.

Nagel, S.N., Steffen, I.G., Schwartz, S., Hamm, B., Elgeti, T.: Age-dependent diagnostic accuracy of clinical scoring systems and D-dimer levels in the diagnosis of pulmonary embolism with computed tomography pulmonary angiography (CTPA). Eur Radiol. 2019:4563-4571.

Ševa, J., (...) Lamping, M., Rieke, D., (...) Starlinger, J., Keilholz, U., Leser, U.: VIST - a Variant-Information Search Tool for precision oncology. BMC Bioinformatics. 2019;20(1):429.

Schumann, F., Blanc, E., Messerschmidt, C., Blankenstein, T., Busse, A., Beule, D.: SigsPack, a package for cancer mutational signatures. BMC Bioinformatics. 2019;20(1):450.

Çakmak-Görür N, Radke J, Rhein S, (...) Heppner FL, Blankenstein T, Pezzutto A.: Intracellular expression of FLT3 in Purkinje cells: implications for adoptive T-cell therapies. Leukemia. 2019

Horwitz S, O'Connor OA, Pro B, (...) Manley T, Trümper L; ECHELON-2 Study Group.: Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019

Nagel SN, Kim D, Wylutzki T, (...) Schwartz S, Penzkofer T, Hamm B, Elgeti T.:  Diagnostic Performance and Reliability of Non-Enhanced Imaging Characterization Quotients for the Differentiation of Infectious and Malignant Pulmonary Nodules in Hematological Patients Using 3T MRI.  Rofo. 2019

Kotrova M, Volland A, Kehden B, (...) Schwartz S, Baldus CD, Gökbuget N, Brüggemann M.:  Comparison of minimal residual disease levels in bone marrow and peripheral blood in adult acute lymphoblastic leukemia. Leukemia. 2019

Klinghammer K, Gauler T, Dietz A, (...) Martus P, Knoedler M, Keilholz U:  Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108).  Eur J Cancer. 2019

Barnell EK, Waalkes A, Mosior MC, (...) Rieke D, (...) Griffith M, Salipante SJ, Griffith OL:  Open-Sourced CIViC Annotation Pipeline to Identify and Annotate Clinically Relevant Variants Using Single-Molecule Molecular Inversion Probes.  JCO Clin Cancer Inform. 2019

Schwartz S, Cornely OA, Hamed K, (...) Rahav G, Herbrecht R, Heinz WJ.: Isavuconazole for the treatment of patients with invasive fungal diseases involving the central nervous system.  Med Mycol. 2019

Garralda E, Fiedler W, Matos I, (...) Klinghammer K, (...) Baumeister H, Ochsenreither S, Zurlo A.: Preliminary results in colorectal cancer (CRC) patients enrolled in the GATTO study, a phase I study of Tomuzotuximab in combination with Gatipotuzumab in patients with EGFR positive solid tumors.  Ann Oncol. 2019 

Schnürch HG, Ackermann S, Alt-Radtke CD (...) Letsch A (...) Weikel W, Wölber L, Hampl M.: Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1060-1078

Schnürch HG, Ackermann S, Alt-Radtke CD (...) Letsch A (...) Weikel W, Wölber L, Hampl M: Diagnosis, Therapy and Follow-up of Vaginal Cancer and Its Precursors. Guideline of the DGGG and the DKG (S2k-Level, AWMF Registry No. 032/042, October 2018). Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1060-1078

Wagner AD, Oertelt-Prigione S, Adjei A (...) Letsch A (...) Moehler M, Peters S, Özdemir BC: Gender medicine and oncology: report and consensus of an ESMO workshop. Ann Oncol. 2019 Dec 1;30(12):1914-1924

Hartkopf AD, Müller V, Wöckel A (...) Lüftner D: Translational Highlights in Breast and Ovarian Cancer 2019 - Immunotherapy, DNA Repair, PI3K Inhibition and CDK4/6 Therapy. Geburtshilfe Frauenheilkd. 2019 Dec;79(12):1309-1319

Lüftner D (...) Untch M, Wuerstlein R, Thill M: Treatment of Early Breast Cancer Patients: Evidence, Controversies, Consensus: Focusing on Systemic Therapy - German Experts' Opinions for the 16th International St. Gallen Consensus Conference (Vienna 2019). Breast Care (Basel). 2019 Oct;14(5):315-324

Welslau M, Hartkopf AD, Müller V (...) Lüftner D (...) Tesch H, Schneeweiss A, Fehm TN: Update Breast Cancer 2019 Part 5 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies in Patients with Advanced Breast Cancer. Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1090-1099

Schütz F, Fasching PA, Welslau M (...) Lüftner D, Fehm TN, Schneeweiss A, Müller V: Update Breast Cancer 2019 Part 4 - Diagnostic and Therapeutic Challenges of New, Personalised Therapies for Patients with Early Breast Cancer. Geburtshilfe Frauenheilkd. 2019 Oct;79(10):1079-1089

Thill M, Jackisch C, Janni W (...) Lüftner D (...) Witzel I, Wöckel A, Ditsch N: AGO Recommendations for the Diagnosis and Treatment of Patients with Locally Advanced and Metastatic Breast Cancer: Update 2019. Breast Care (Basel). 2019 Aug;14(4):247-255

Ditsch N, Untch M, Thill M (...) Lüftner D (...) Wenz F, Witzel I, Wöckel A: AGO Recommendations for the Diagnosis and Treatment of Patients with Early Breast Cancer: Update 2019. Breast Care (Basel). 2019 Aug;14(4):224-245

Pivot X, Pegram M, Cortes J, Lüftner D (...) Kim Y, Kim C: Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer. Eur J Cancer. 2019 Oct;120:1-9

Untch M, Thomssen C, Bauerfeind I (...) Lüftner D (...) Wuerstlein R, Fasching PA, Harbeck N: Primary Therapy of Early Breast Cancer: Evidence, Controversies, Consensus: Spectrum of Opinion of German Specialists on the 16th St. Gallen International Breast Cancer Conference (Vienna 2019). Geburtshilfe Frauenheilkd. 2019 Jun;79(6):591-604

Kolberg HC, Schneeweiss A, Fehm TN (...) Lüftner D (...) Schütz F, Fasching PA, Brucker SY: Update Breast Cancer 2019 Part 3 - Current Developments in Early Breast Cancer: Review and Critical Assessment by an International Expert Panel. Geburtshilfe Frauenheilkd. 2019 May;79(5):470-482

Lüftner D: Approval by Authorities Does Not Allow For Suboptimal Study Conduct but Offers New Academic Possibilities. Breast Care (Basel). 2019 Mar;14(1):2-3

Janni W, Schneeweiss A, Müller V (...) Lüftner D (...) Fehm TN, Kolberg HC, Ettl J: Update Breast Cancer 2019 Part 2 - Implementation of Novel Diagnostics and Therapeutics in Advanced Breast Cancer Patients in Clinical Practice. Geburtshilfe Frauenheilkd. 2019 Mar;79(3):268-280

Hartkopf AD, Müller V, Wöckel A (...) Lüftner D (...) Overkamp F, Schneeweiss A, Tesch H: Update Breast Cancer 2019 Part 1 - Implementation of Study Results of Novel Study Designs in Clinical Practice in Patients with Early Breast Cancer. Geburtshilfe Frauenheilkd. 2019 Mar;79(3):256-267

Armbrust R, Neeb C, Thuss-Patience P, Lüftner D (...) Richter R, Keller M, Sehouli J: Patients' perspectives towards malignant ascites: results of a prospective observational trial regarding expectations, characteristics and quality of life-a study of the North-Eastern-German Society of Gynecological Oncology. Arch Gynecol Obstet. 2019 May;299(5):1385-1389